Pregabalin Capsule
Product Images NDC 71610-946

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-946). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0946 30)

Label for Pregabalin 225 mg capsules, containing 30 capsules. The label shows storage instructions, manufacturer SciGen Pharmaceuticals Inc., and packaging by Aphena Pharma Solutions, Cookeville, TN. It includes warnings about habit forming and keeping out of reach of children. The National Drug Code (NDC) is 71610-946-30.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure of the active ingredient Pregabalin, displaying its molecular arrangement including the amino (NH2) and carboxyl (CO2H) functional groups.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph depicting the percent of patients improved versus the percent improvement in pain from baseline for Pregabalin at doses of 200 mg, 100 mg, and 25 mg taken three times a day, compared to placebo. The graph shows distinct lines for each dose and placebo indicating efficacy trends.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph depicting the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. Two lines compare Pregabalin 100 mg three times a day and placebo groups, showing the percentage of patients reporting pain improvement outcomes.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph depicting the percent of patients improved plotted against the percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg two times a day, Pregabalin 150 mg two times a day, Pregabalin 75 mg two times a day, and placebo. The lines show varying levels of patient improvement corresponding to the different doses of Pregabalin and placebo.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph depicting the relationship between percent improvement in pain from baseline (x-axis) and percent of patients improved (y-axis). It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing different response rates across the improvement spectrum.*

FDA Label Image

Figure 5 (Pregabalin 06)

A graph showing percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating their relative effectiveness across different levels of pain improvement.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar chart comparing responder rates (%) across different dosages of Pregabalin and placebo in two studies, labeled Study E1 and Study E3. The x-axis shows the dosage groups including placebo, and the y-axis represents responder rates ranging from 0% to 60%. Study E1 includes placebo and dosages from 150 mg/day to 600 mg/day, while Study E3 includes placebo and dosages of 150 mg/day and 600 mg/day. Each bar's height corresponds to the responder rate for that group.*

FDA Label Image

Figure 7 (Pregabalin 08)

A dose-response chart showing median percent seizure reduction from baseline on the y-axis and dose in mg/day on the x-axis for four different studies labeled as Study E1 BD, Study E2 TID, Study E3 BD, and Study E3 TID. The graph includes data points for placebo and increasing doses up to 600 mg/day, with significant p-values indicated for the comparisons.*

FDA Label Image

Figure 8 (Pregabalin 09)

A bar graph depicting responder rates (%) for three groups: Placebo (22.6%, n=93), 2.5 mg/kg/day Pregabalin (29.1%, n=103), and 10 mg/kg/day Pregabalin (40.6%, n=96). The y-axis represents responder rate percentage from 0 to 60%, with higher rates observed at increased dosage levels.*

FDA Label Image

Figure 9 (Pregabalin 10)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares four groups: Pregabalin 600mg daily dose, Pregabalin 450mg daily dose, Pregabalin 300mg daily dose, and placebo, with each represented by different line styles.*

FDA Label Image

Figure 10 (Pregabalin 11)

A line chart comparing the estimated percentage of subjects without LTR (likely loss to relapse) over a period of 180 days for Pregabalin versus placebo. The vertical axis represents the estimated percentage of subjects without LTR, ranging from 0% to 100%, and the horizontal axis represents days from 0 to 180. The Pregabalin group shows a higher percentage of subjects without LTR over time compared to the placebo group.*

FDA Label Image

Figure 11 (Pregabalin 12)

A line graph comparing the percentage of subjects improved over time from baseline to Week 12, showing two data series labeled Pregabalin and Placebo. The x-axis represents percent improvement, and the y-axis represents the percent of subjects improved. The Pregabalin line is consistently above the Placebo line, indicating greater improvement among subjects treated with Pregabalin.*

FDA Label Image

Figure 12 (Pregabalin 13)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to Week 16 BOCF between Pregabalin and placebo groups. The x-axis shows percent improved from baseline to Week 16, and the y-axis shows the percent of subjects improved. The solid line represents Pregabalin, and the dashed line represents placebo, with the Pregabalin group consistently showing higher improvement percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.